Dogwood Therapeutics, Inc.

Biotechnology • Healthcare • Alpharetta, GA, United States • DWTX (NCM)

Dogwood Therapeutics, Inc., a development-stage biotechnology company, focuses on the development of medicine to treat pain and fatigue-related disorders. Its lead product candidates include IMC-1, a fixed dose combination of famciclovir and celecoxib that has completed Phase 2b clinical trial to treat fibromyalgia; Halneuron, which is in Phase 2b clinical trial for the treatment of chemotherapy-induced neuropathic pain and cancer pain, as well as pre-clinical trial for burn and ocular pain; and IMC-2, a combination of valacyclovir and celecoxib in Phase 2 clinical trial for the treatment of long-COVID and post-acute sequelae of COVID-19 infection. The company was formerly known as Virios Therapeutics, Inc. and changed its name to Dogwood Therapeutics, Inc. in October 2024. The company was incorporated in 2012 and is based in Alpharetta, Georgia.

866 620 8655 44 Milton Avenue, Alpharetta, GA 30009, United States

Stock Performance (90 Days)

Data through Dec 26, 2025

Price updates on page refresh. Intraday quotes available during market hours (9:30 AM - 4:00 PM EST).

Layoff History

No layoff events recorded for this company.

Recent News

Dogwood Therapeutics stock plummets after Phase 2b interim results - Investing.com

Investing.com • Dec 22

Early trial hints at new option for chemo-related nerve pain sufferers - Stock Titan

Stock Titan • Dec 22

Dogwood Therapeutics Announces Positive Interim Phase 2b - GlobeNewswire

GlobeNewswire • Dec 22

What's Driving the Market Sentiment Around Dogwood Therapeutics Inc? - Benzinga

Benzinga • Dec 24

Aug Big Picture: Will Dogwood Therapeutics Inc stock continue upward momentum - Trade Risk Assessment & Safe Entry Point Alerts - moha.gov.vn

moha.gov.vn • Dec 25

Other Biotechnology Companies

Vertex Pharmaceuticals Inc. / MA

$118.68B market cap

Regeneron Pharmaceuticals, Inc.

$82.72B market cap

Alnylam Pharmaceuticals, Inc.

Frequently Asked Questions

Has Dogwood Therapeutics, Inc. had layoffs?

No layoff events have been recorded for Dogwood Therapeutics, Inc. in our database. This could mean the company has not conducted significant layoffs, or any layoffs have not been publicly reported.

How many employees does Dogwood Therapeutics, Inc. have?

Dogwood Therapeutics, Inc. has approximately 12 employees.

What industry is Dogwood Therapeutics, Inc. in?

Dogwood Therapeutics, Inc. operates in the Biotechnology industry, within the Healthcare sector.

Is Dogwood Therapeutics, Inc. a publicly traded company?

Yes, Dogwood Therapeutics, Inc. is publicly traded under the ticker symbol DWTX on the NCM. The company has a market capitalization of approximately $0.12 billion.

Where is Dogwood Therapeutics, Inc. headquartered?

Dogwood Therapeutics, Inc. is headquartered in Alpharetta, GA, United States at 44 Milton Avenue, Alpharetta, GA 30009, United States.

Disclaimer

Data aggregated from public sources including WARN notices, SEC filings, press releases, and market data. While we strive for accuracy, information is provided "as-is" for informational purposes only. Always verify critical information with official company sources.

This information does not constitute investment, financial, legal, or career advice. See our Terms of Service, Privacy Policy, and About page for more information.

Found an error? Report it here.